Published in Clin Exp Immunol on November 01, 1975
Anti-self receptors. I. Direct detection of H-2L region-restricted receptors on murine thymocytes. J Exp Med (1980) 0.95
Increase in autologous erythrocyte binding by T cells with ageing in man. Clin Exp Immunol (1977) 0.92
Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis. Clin Exp Immunol (1976) 0.91
Effects of ageing, surface sialic acid and glycopeptides of erythrocytes on auto-rosettes in man. Clin Exp Immunol (1978) 0.90
Bovine lymphocytes: recognition of cells forming spontaneous (E) rosettes. Clin Exp Immunol (1977) 0.90
Human post-thymic precursor cells in health and disease. I. Characterization of the autologous rosette-forming T cells as post-thymic precursors. Immunology (1981) 0.88
Induction of human autorosette forming cells by phorbol myristate acetate. Clin Exp Immunol (1982) 0.82
Erythrocyte autoimmune disorder: red cell antibodies and the human allogeneic rosette test. Clin Exp Immunol (1980) 0.75
Autologous rosette forming cells in patients with renal diseases. Clin Exp Immunol (1983) 0.75
Autologous rosette-forming T cells regulate responses of T cells. Phenotypic and functional analysis of suppressor cells generated from autologous rosette-forming T cells after autologous mixed lymphocyte reactions. J Clin Invest (1981) 0.75
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet (1971) 7.98
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
Rosette-formation between human lymphocytes and sheep red cells not involving immunoglobulin receptors. Int Arch Allergy Appl Immunol (1970) 5.92
Cell surface markers for human T and B lymphocytes. Eur J Immunol (1974) 2.70
Rosetting of human red blood cells to thymocytes and thymus-derived cells. Clin Exp Immunol (1973) 2.39
The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. J Immunol (1974) 2.19
Inhibition of human lymphocyte rosetting by anti-T sera. Nat New Biol (1973) 1.45
The interaction of lymphocytes with autologous red cells. J Allergy Clin Immunol (1972) 1.37
Spontaneous rosettes as a T-lymphocyte marker: a modified method giving consistent results. SRBC rosettes. J Immunol Methods (1974) 1.28
Human T lymphocytes form rosettes with autologous and allogeneic human red blood cells. Clin Immunol Immunopathol (1975) 1.26
Studies on the human T-lymphocyte population. II. The use of a T-cell specific antibody in the partial isolation and characterization of the human lymphocyte receptor for sheep red blood cells. J Immunol (1974) 1.17
Rosette formation by human thymocytes. Cell Immunol (1973) 1.17
Letter: Auto-rosette formation by human thymocytes and lymphocytes. Lancet (1974) 1.14
Studies on the human T-lymphocyte population. I. The development and characterization of a specific anti-human T-cell antibody. J Immunol (1974) 1.13
Ageing in vivo and neuraminidase treatment of rabbit erythrocytes: influence on half-life as assessed by 51Cr labelling. Hoppe Seylers Z Physiol Chem (1975) 1.00
Letter: Self and not-self. Lancet (1974) 0.98
Quantitative study of cells reacting to skin allografts. Nature (1970) 0.97
SEPARATION OF ERYTHROCYTES OF DIFFERENT AGES. Clin Chem (1965) 0.95
[Exploration of thymic function in man. II. The "sheep red cell rosette" phenomenon, a T-cell marker in man]. Nouv Presse Med (1974) 0.92
Quantitative haemagglutination. 4. Effect of neuraminidase treatment on agglutination by blood group antibodies. Br J Haematol (1973) 0.89
SEPARATION OF RABBIT RED CELLS BY DENSITY METHODS AND CHARACTERISTICS OF SEPARATED LAYERS. J Cell Physiol (1965) 0.88
Letter: Rosetting cells in autoimmune haemolytic anaemia. Lancet (1974) 0.88
Rosette formation between human T-lymphocytes and unsensitized rhesus monkey erythrocytes. Clin Immunol Immunopathol (1974) 0.87
Quantitative haemagglutination. 3. Stuies of separated populations of human red blood cells of different densities. Br J Haematol (1970) 0.87
Letter: Spontaneous autorosettes in man. Lancet (1975) 0.84
Significance of spontaneous autorosettes in rats. Eur J Immunol (1975) 0.84
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38
Dendritic cells as the terminal stage of monocyte differentiation. J Immunol (1998) 1.87
Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol (1997) 1.72
Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A (1999) 1.66
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56
The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol (1998) 1.51
Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol (1990) 1.35
Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication. J Exp Med (1988) 1.31
The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. J Immunol (2001) 1.29
A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol (1986) 1.25
HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors. AIDS (1989) 1.24
Acquired immunodeficiency syndrome in France. Lancet (1983) 1.21
Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis. J Exp Med (1989) 1.20
Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses (1992) 1.17
Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood (1996) 1.16
Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood (1996) 1.11
Functions of HIV envelope glycans. Trends Biochem Sci (1994) 1.08
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses (1999) 1.05
Lipopolysaccharide can block the potential of monocytes to differentiate into dendritic cells. J Leukoc Biol (1999) 1.00
Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. Lymphology (1990) 1.00
Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J Virol (1992) 0.99
The effect of in vitro human immunodeficiency virus infection on dendritic-cell differentiation and function. Blood (1996) 0.99
Is there correlation of T cell proliferative functions and surface marker phenotypes in patients with acquired immune deficiency syndrome or lymphadenopathy syndrome? Clin Exp Immunol (1985) 0.99
Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage. Virology (1992) 0.98
Lymphadenopathy-associated-virus infection and acquired immunodeficiency syndrome. Annu Rev Immunol (1986) 0.97
Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS (1998) 0.97
Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules. AIDS (1988) 0.96
Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans. AIDS Res Hum Retroviruses (1992) 0.96
Monoclonal antibodies to the human immunodeficiency virus p18 protein cross-react with normal human tissues. AIDS (1988) 0.96
Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker. J Infect Dis (1992) 0.95
Lectin-carbohydrate interactions and infectivity of human immunodeficiency virus type 1 (HIV-1). AIDS Res Hum Retroviruses (1992) 0.95
Immunogenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T-cell and B-cell epitopes in immunized chimpanzees. AIDS Res Hum Retroviruses (1990) 0.94
Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. Glycobiology (2000) 0.94
Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells. Blood (2000) 0.92
Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). Virology (1995) 0.92
Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. FEBS Lett (1994) 0.91
Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis. Clin Exp Immunol (1976) 0.91
Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog AIDS Pathol (1989) 0.90
Effects of ageing, surface sialic acid and glycopeptides of erythrocytes on auto-rosettes in man. Clin Exp Immunol (1978) 0.90
[Functional inhibition by cyclosporin A of the lymphocyte receptor for the AIDS virus (HIV)]. C R Acad Sci III (1986) 0.89
CD13/N-aminopeptidase is involved in the development of dendritic cells and macrophages from cord blood CD34(+) cells. Blood (2000) 0.89
The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology (1998) 0.89
Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res Hum Retroviruses (1989) 0.88
Suppression of lymphocyte reactivity by blood transfusions in uremic patients. I. Proliferative responses. Transplantation (1983) 0.87
Cell-free HIV in lymph nodes of patients with AIDS and generalized lymphadenopathy. N Engl J Med (1988) 0.87
A molecular mechanism of inhibition of HIV-1 binding to CD4+ cells by monoclonal antibodies to gp110. AIDS (1988) 0.86
Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol (1993) 0.86
Double HIV-1 and HIV-2 seropositivity among blood donors. Lancet (1987) 0.85
T-lymphocyte progenitors in man: phenotypic characterization of blood and bone marrow T-colony forming cells. Immunology (1985) 0.85
Abnormal in vitro proliferation and differentiation of T colony forming cells in AIDS patients and clinically normal male homosexuals. Clin Exp Immunol (1985) 0.85
Significance of spontaneous autorosettes in rats. Eur J Immunol (1975) 0.84
Letter: Spontaneous autorosettes in man. Lancet (1975) 0.84
Abnormal in vitro proliferation and differentiation of T colony-forming cells in patients with lymphadenopathy syndrome. Blood (1986) 0.84
The Lewis system: New histocompatibility antigens in renal transplantation. Lancet (1978) 0.84
Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients. AIDS (1989) 0.84
Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate. Biochim Biophys Acta (1992) 0.83
Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160. J Virol (1993) 0.83
Clinical and immunological restoration in patients with AIDS after marrow transplantation, using lymphocyte transfusions from the marrow donor. Transplantation (1987) 0.83
HIV-1 diversity in Morocco. AIDS (1997) 0.82
High production of the acquired immunodeficiency syndrome virus (lymphadenopathy-associated virus) by human T lymphocytes stimulated by streptococcal mitogenic toxins. J Clin Microbiol (1986) 0.82
Recipient's HLA-DR phenotype and renal graft outcome. Transplantation (1983) 0.81
Membrane glycolipids and human immunodeficiency virus infection of primary macrophages. AIDS Res Hum Retroviruses (1996) 0.81
T-lymphocyte progenitors in man: biochemical characterization of a colony promoting activity (CPA) active on immature precursors. Immunology (1984) 0.81
Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol (1991) 0.81
Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees. AIDS (1991) 0.81
Identification of mature and immature human thymic dendritic cells that differentially express HLA-DR and interleukin-3 receptor in vivo. J Leukoc Biol (2000) 0.81
Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection. Blood (1990) 0.81
In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. Virology (1995) 0.81
Large fragments of nef-protein and gp110 envelope glycoprotein from HIV-1. Synthesis, CD analysis and immunoreactivity. Int J Pept Protein Res (1990) 0.80
Prospective study of HIV I seropositive patients in hemodialysis centers. Clin Nephrol (1988) 0.80
Effect of mannosylated derivatives on HIV-1 infection of macrophages and lymphocytes. Glycobiology (1997) 0.80
Carbohydrate binding properties of the envelope glycoproteins of human immunodeficiency virus type 1. Glycoconj J (1992) 0.80
Exogenous interleukin-2 and mitogen responses in AIDS patients. Lancet (1984) 0.79
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses (1995) 0.79
Infection of monocytic cells by HIV1: combined role of FcR and CD4. Res Virol (1991) 0.79
Relationship between anti-p24 antibody levels and p24 antigenemia in HIV-infected patients. AIDS Res Hum Retroviruses (1993) 0.79
Soluble glycosaminoglycans Do not potentiate RANTES antiviral activity on the infection of primary macrophages by human immunodeficiency virus type 1. Virology (2000) 0.79
Lymphocytotoxic antibodies and bone marrow grafts from HLA-identical siblings. I. HLA antibodies. Transplantation (1978) 0.79
Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc (2009) 0.79
Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1). FEBS Lett (1993) 0.79
Early and specific diagnosis of seropositivity to HIVs by an enzyme-linked immunosorbent assay using env-derived synthetic peptides. AIDS (1990) 0.78
[Infectious pulmonary complications observed after renal transplantation (analysis of 104 cases)]. Ann Med Interne (Paris) (1973) 0.78
HLA-independent cell-mediated alloimmunity detected by a microcytotoxicity assay. Transplantation (1978) 0.78
Frequency of the CCR5delta32 allele in the Moroccan population. AIDS Res Hum Retroviruses (2000) 0.78
Probable role of suppressor cells and factors in kidney graft survival. Transplant Proc (1982) 0.78
A monoclonal antibody directed to sulfatide inhibits the binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein to macrophages but not their infection by the virus. Biochim Biophys Acta (1994) 0.78
HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages. AIDS Res Hum Retroviruses (1997) 0.78
Involvement of the HIV-1 external envelope glycoprotein 120 (gp120) C2 region in gp120 oligomerization. Biochim Biophys Acta (1997) 0.77
Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clin Exp Immunol (1995) 0.77
Extensive C-terminal deletion in human immunodeficiency virus type 1 Env glycoprotein arising after long-term culture of chronically infected cells. J Gen Virol (1994) 0.77
The role of calcium and N-linked glycans in the oligomerization and carbohydrate binding properties of human immunodeficiency virus external envelope glycoprotein. Glycoconj J (1994) 0.77
Primary in vitro sensitization of human T-helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein. Vaccine (1994) 0.77
Blood transfusions suppress lymphocyte reactivity in uremic patients. II. Evidence for soluble suppressor factors. Transplantation (1983) 0.77
HIV infection: facts and hypotheses. Immunol Today (1986) 0.77
Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages. AIDS Res Hum Retroviruses (1998) 0.77
Follicle lysis in lymph nodes from homosexual men. Blood (1986) 0.77